Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning.
Am J Transplant
; 14(4): 750-63, 2014 Apr.
Article
en En
| MEDLINE
| ID: mdl-24592900
ABSTRACT
Owing to the adverse effects of immunosuppression and an inability to prevent chronic rejection, there is a pressing need for alternative strategies to control alloimmunity. In three decades, regulatory T cells (Tregs) have evolved from a hypothetical mediator of adoptively transferred tolerance to a well-defined population that can be expanded ex vivo and returned safely to patients in clinical trials. Herein, we review the historical developments that have permitted these advances and the current status of clinical trials examining Tregs as a cellular therapy in transplantation. We conclude by discussing the critical unanswered questions that face this field in the coming years.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trasplante de Órganos
/
Linfocitos T Reguladores
/
Tolerancia al Trasplante
/
Tratamiento Basado en Trasplante de Células y Tejidos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Am J Transplant
Asunto de la revista:
TRANSPLANTE
Año:
2014
Tipo del documento:
Article
País de afiliación:
Reino Unido